de KlerkJ., van DierenE., Van het SchipA., HoekstraA., ZonnenbergB., van DijkA., RutgersD., BlijamG., van RijkP.: Bone marrow adsorbed dose of rhenium-186 HEDP and relationship with decreased platelet counts. Nucl. Med., 37: 38–41, 1996.
2.
de KlerkJ., van DijkA., Van het SchipA.D., ZonnenbergB., van RijkP.: Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. Nucl. Med., 33: 646–651, 1992.
3.
Mallinckrodt Medical:Rhenium-186 HEDP (186Re) injection. User guide.
4.
MaxonH., SchroderL., HertzbergV., ThomasS., EnglaroE., SamaratungaR., SmithH., MoultonS., WilliamsC., EhrardtG., SchneiderH.: Rhenium-186 (Sn) HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. Nucl. Med., 32: 1877–1881, 1991.
5.
SchwaigerM.: The importance of radionuclide therapy and its ethical aspects. The update, 1: 8–10, 1995.
6.
SerafiniA.: Current status of systemic intravenous radiopharmaceuticals for the treatment of painful bone metastatic disease. Int. J. Radiation Oncology Biol. Phys., 30: 1187–1194, 1994.
7.
ZonnenbergB.: Experience with Re-186 HEDP: the view of an involved oncologist. The update, 1: 11–16, 1995.
